login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 




Featured Highlights
1 - 20 of 151   Items
SIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer

SIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer

Tuesday, 30 Sep 2014
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer endorse radioembolisation, specifically with yttrium-90 (Y90) resin microspheres, as a clinically proven technology to “prolong time to liver tumour progression” in patients who have failed to respond to available chemotherapy options. SIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer
Sirtex expands business into Brazil

Sirtex expands business into Brazil

Tuesday, 09 Sep 2014
Sirtex has announced the expansion of its business in Latin America. Sirtex’s SIR-Spheres microspheres are now available to treat inoperable liver tumours in Brazil. Sirtex expands business into Brazil

First patient enrolled in global phase III OPTIMA study of ThermoDox in primary liver cancer

Friday, 05 Sep 2014
Celsion Corporation has announced that the first patient has been enrolled in its pivotal phase III OPTIMA study of ThermoDox in combination with optimised radiofrequency ablation in patients with hepatocellular carcinoma. The first patient was treated at Kyungpook National University Hospital in South Korea. First patient enrolled in global phase III OPTIMA study of ThermoDox in primary liver cancer
DC Bead approved by China Food and Drug Administration

DC Bead approved by China Food and Drug Administration

Tuesday, 02 Sep 2014
BTG and its partner SciClone Pharmaceuticals have announced that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularised tumours. DC Bead approved by China Food and Drug Administration

Study identifies tumour-promoting role of EGFR present in liver macrophages

Monday, 01 Sep 2014
A study group at the Comprehensive Cancer Centre of Medical University of Vienna and AKH Vienna under the guidance of Maria Sibilia from the Institute for Cancer Research has discovered that tumorigenisis of epidermal growth factor receptor (EGFR) does not, as previously assumed, depend on its presence within the tumour cell, but rather from its activity in the cells adjacent to the tumour. Study identifies tumour-promoting role of EGFR present in liver macrophages
The microenvironment of solid tumours matters

The microenvironment of solid tumours matters

Friday, 08 Aug 2014
Despite the rapid growth of imaging and treatment options in interventional oncology, one area that has been poorly understood and overlooked by the interventional community is the role of the tumour microenvironment and its impact on the delivery of therapeutic agents, writes Aravind Arepally. The microenvironment of solid tumours matters

Vascular Solutions launches Gel-Bead bioresorbable embolization spheres

Friday, 01 Aug 2014
Vascular Solutions has announced the US market launch of its Gel-Bead embolization spheres for the treatment of hypervascular tumours. Vascular Solutions launches Gel-Bead bioresorbable embolization spheres
Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment

Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment

Wednesday, 23 Jul 2014
The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star (DFINE) tumour ablation system. Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment
Liver tumour ablation more predictable with Emprint

Liver tumour ablation more predictable with Emprint

Thursday, 17 Jul 2014
Covidien has unveiled an advanced ablation system that offers physicians predictable results regardless of the target location or tissue type. Liver tumour ablation more predictable with Emprint
Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Tuesday, 08 Jul 2014
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or small intestine can result in serious complications, especially gastrointestinal ulcerations, particularly with Y-90 microspheres. Now, temporary antireflux devices are available that appear to provide both adequate retrograde and antegrade protection against nontarget delivery of cytotoxic agents, Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Terumo obtains regulatory approvals for marketing MicroThermX in additional countries

Friday, 27 Jun 2014
BSD Medical Corporation reported that Terumo Europe NV (Terumo) has obtained approvals to market and import the MicroThermX Microwave Ablation System in South Africa, Dubai, Qatar, and Jordan. Terumo obtains regulatory approvals for marketing MicroThermX in additional countries
Three millimetre “ice ball” margin beyond renal tumours adequate for effective cryoablation

Three millimetre “ice ball” margin beyond renal tumours adequate for effective cryoablation

Friday, 13 Jun 2014
The results from a small, animal study challenge previously unsubstantiated published reports claiming that a five to 10mm “ice ball” margin beyond the tumour is necessary for effective cryoablation. Three millimetre “ice ball” margin beyond renal tumours adequate for effective cryoablation

Philips expands interventional oncology portfolio with EmboGuide to see, reach and treat tumour lesions

Friday, 16 May 2014
New live 3D image guidance tool enhances tumour embolization procedures on Philips’ interventional X-ray systems. Philips expands interventional oncology portfolio with EmboGuide to see, reach and treat tumour lesions
Reducing the perils of ablation for thermally sensitive adjacent organs

Reducing the perils of ablation for thermally sensitive adjacent organs

Friday, 16 May 2014
Over the years, we have seen a rapid development of tools, tricks and techniques that enable ablation of tumours located in regions that are in close proximity to thermally sensitive organs or structures, writes Nishita Kothary (Stanford University, USA). Reducing the perils of ablation for thermally sensitive adjacent organs

Surefire system vs. end hole catheter clinical trial eliminates patient variables

Monday, 05 May 2014
Preliminary observations from the trial were presented at the Global Embolization Symposium and Technologies US (GEST US meeting, 1–4 May, San Francisco, USA) and show increased tumour penetration with the Surefire system. Surefire system vs. end hole catheter clinical trial eliminates patient variables
Interventional radiology techniques and results for the management of neuroendocrine liver metastases

Interventional radiology techniques and results for the management of neuroendocrine liver metastases

Wednesday, 30 Apr 2014
Interventional radiology techniques are widely performed and useful in liver metastases from neuroendocrine tumours, but the level of scientific proof is paradoxically low, especially when considering that these techniques are used in patients with cancer, write Maxime Ronot and Valérie Vilgrain Interventional radiology techniques and results for the management of neuroendocrine liver metastases
COSY trial shows highly reduced radioembolization procedure time and radiation dose

COSY trial shows highly reduced radioembolization procedure time and radiation dose

Friday, 28 Mar 2014
Surefire Medical has announced that the COSY clinical trial (Coiling vs. Surefire infusion system in Y90) showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the Surefire Infusion System without coiling. COSY trial shows highly reduced radioembolization procedure time and radiation dose

Sirtex and Guerbet announce collaboration in clinical studies in liver cancer

Thursday, 27 Mar 2014
Sirtex and Guerbet have announced that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. Sirtex and Guerbet announce collaboration in clinical studies in liver cancer

Cancer specialists to head to Berlin to attend ECIO

Thursday, 27 Mar 2014
The world’s leading radiologists, oncologists and surgeons will head to Germany in April for the European Conference on International Oncology (ECIO, 23-26 April, Berlin, Germany). Cancer specialists to head to Berlin to attend ECIO
Radioembolization offers new, safe treatment for metastatic breast cancer

Radioembolization offers new, safe treatment for metastatic breast cancer

Monday, 24 Mar 2014
The largest study of its kind to date shows that minimally invasive radioembolization may slow metastatic disease progression in liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology’s 39th Annual Scientific Meeting (22–27 March, San Diego, USA). Radioembolization offers new, safe treatment for metastatic breast cancer
Found: 151   Displaying: 1-20
Results: 1 2 3 4 5 Next Go to:

Related Section


Clinical Trials
Interventional Oncology News
Interventional Oncology Supplement
Key Opinion Leaders discuss the role of Biocompatible's DC Bead at CIRSE and ILCA
IR Views
Literature
Oncology Useful Links

Related Feeds


Most popular


First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

CIRSE 2014 audience needs more evidence before they support drug-elution in the superficial femoral artery
Friday, 26 Sep 2014
The audience in the CIRSE 2014 “Controversies in superficial femoral artery treatment” session failed to endorse two motions pertaining to drug-elution in this anatomical segment in the annual ... CIRSE 2014 audience needs more evidence before they support drug-elution in the superficial femoral artery

Features


What the trials have taught us about aggressive therapy of deep venous thrombosis
Thursday, 25 Sep 2014
Although current evidence in favour of catheter-directed thrombolysis for deep venous thrombosis may not be robust enough to allow for a shift in clinical practice, that may soon change with strict ... What the trials have taught us about aggressive therapy of deep venous thrombosis

The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Profiles


José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions